Derek A. Bertocci net worth and biography

Derek Bertocci Biography and Net Worth

CFO of Guardant Health

Derek Bertocci CPA is no longer serves as Chief Financial Officer of the Company effective 12/4/2020. Prior to joining us, Mr. Bertocci served as Senior Vice President and Chief Financial Officer of Achaogen Inc. from February 2014 to December 2015. Prior to that, Mr. Bertocci was Senior Vice President and Chief Financial Officer of Accuray Incorporated, a publicly traded radiation oncology company, from January 2009 to September 2013. From October 2006 through December 2008, Mr. Bertocci served as the Chief Financial Officer of BioForm Medical, Inc., a publicly traded medical aesthetics company. From June 2005 to July 2006, he was Chief Financial Officer of Laserscope, a publicly traded provider of lasers and fiber optic devices for urology and aesthetic surgery. Prior to that, Mr. Bertocci spent a number of years in various roles at VISX Incorporated, a publicly traded provider of systems for laser vision correction surgery, including as Chief Financial Officer from March 2004 to May 2005 and Vice President and Controller from 1998 to March 2004. Mr. Bertocci holds a B.A. degree from Stanford University and an M.B.A. degree from the University of Southern California. Mr. Bertocci is also a Certified Public Accountant (inactive)

What is Derek A. Bertocci's net worth?: The estimated net worth of Derek A. Bertocci is at least $426,353.73 as of September 1st, 2020. Mr. Bertocci owns 14,113 shares of Guardant Health stock worth more than $426,354 as of November 15th. This net worth evaluation does not reflect any other investments that Mr. Bertocci may own. Learn More about Derek A. Bertocci's net worth.
How do I contact Derek A. Bertocci?: The corporate mailing address for Mr. Bertocci and other Guardant Health executives is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. Guardant Health can also be reached via phone at (855) 698-8887 and via email at [email protected]. Learn More on Derek A. Bertocci's contact information.
Has Derek A. Bertocci been buying or selling shares of Guardant Health?: Derek A. Bertocci has not been actively trading shares of Guardant Health in the last ninety days. Most recently, Derek A. Bertocci sold 30,100 shares of the business's stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $93.94, for a transaction totalling $2,827,594.00. Following the completion of the sale, the chief financial officer now directly owns 14,113 shares of the company's stock, valued at $1,325,775.22. Learn More on Derek A. Bertocci's trading history.
Who are Guardant Health's active insiders?: Guardant Health's insider roster includes Derek Bertocci (CFO), Ian Clark (Director), Helmy Eltoukhy (CEO), Meghan Joyce (Director), Kumud Kalia (Insider), Samir Kaul (Director), Stanley Meresman (Director), Amelia Merrill (SVP), and Amirali Talasaz (COO). Learn More on Guardant Health's active insiders.
Are insiders buying or selling shares of Guardant Health?: During the last year, Guardant Health insiders bought shares 1 times. They purchased a total of 2,187 shares worth more than $38,972.34. During the last year, insiders at the sold shares 5 times. They sold a total of 8,996 shares worth more than $246,862.40. The most recent insider tranaction occured on November, 13th when Director Meghan V Joyce sold 2,896 shares worth more than $86,590.40. Insiders at Guardant Health own 5.5% of the company. Learn More about insider trades at Guardant Health.
Information on this page was last updated on 11/13/2024.

Derek A. Bertocci Insider Trading History at Guardant Health

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/1/2020	Sell	30,100	$93.94	$2,827,594.00	14,113
8/24/2020	Sell	9,992	$94.39	$943,144.88	44,159
5/22/2020	Sell	9,222	$96.63	$891,121.86	69,872
5/11/2020	Sell	21,862	$92.53	$2,022,890.86	84,049
5/8/2020	Sell	913	$90.40	$82,535.20	84,049
3/23/2020	Sell	19,100	$60.65	$1,158,415.00	100,333
11/18/2019	Sell	25,481	$79.58	$2,027,777.98	99,684
8/19/2019	Sell	42,548	$100.00	$4,254,800.00
5/10/2019	Sell	18,562	$76.30	$1,416,280.60

Derek A. Bertocci Buying and Selling Activity at Guardant Health

Guardant Health Company Overview

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Today's Range

Now: $30.21

$30.03

$31.32

50 Day Range

MA: $23.57

$20.20

$31.61

2 Week Range

Now: $30.21

$15.81

$37.04

Volume

2,020,772 shs

Average Volume

2,071,955 shs

Market Capitalization

$3.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11

Election warning coming true…

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.